New Pharmaceuticals research report from GlobalData is now available from Fast Market Research
Boston, MA -- (SBWIRE) -- 10/10/2013 -- Chronic kidney disease (CKD), or chronic renal disease, is an asymptomatic, long-term condition that damages the kidneys and leads to the loss of kidney function over time. CKD affects people of all ages; however, the risk is higher in people ages 65 years and older. Globally, the estimated prevalence of CKD is 7.2% in adults over the age of 30 years. The disease is more common in women than men, and is also more common in people of African and South Asian origin due to the high prevalence of diabetes in South Asians and hypertension in people of African origin. Based on the glomerular filtration rate, the Kidney Disease Outcomes Quality Initiative (KDOQI) classified CKD into five stages in 2002. Each stage of CKD requires different tests and treatments for management of the disease.
View Full Report Details and Table of Contents
This report provides an overview of the risk factors and the global and historical trends for CKD in the 6MM. In addition, the report includes a 10-year epidemiological forecast (2012-2022) of the prevalent cases of CKD segmented by sex, age (in five-year increments beginning at age 20 and ending at age =85 years), and stage in these markets.
GlobalData's epidemiological forecast is supported by data from country-specific studies published in peer-reviewed journals. GlobalData epidemiologists obtained age- and sex-specific prevalence data for CKD in the 6MM from nationally-representative studies in each country to forecast the total prevalent cases of CKD during the forecast period (2012-2022).
A major strength of this analysis is the use of country-specific data and a uniform methodology across all the markets to forecast the prevalent cases of CKD. In addition, GlobalData epidemiologists provide segmentation of the CKD prevalent cases by stage per the KDOQI guidelines in each market, despite the stage-specific data being limited to certain age groups and stages.
- The Chronic Kidney Disease EpiCast report provides an overview of the risk factors and global trends of chronic kidney disease in the six major markets (6MM) (US, France, Germany, Italy, Spain, and UK). It includes a 10-year epidemiological forecast (2012-2022) of the prevalent cases of chronic kidney disease segmented by age (in five-year increments beginning at age 20 and ending at age =85 years), sex, and stage (1-5) in the 6MM
- The chronic kidney disease epidemiology report is written and developed by Masters- and PhD-level epidemiologists
- In-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 6MM.
Reasons to Get This Report
- Develop business strategies by understanding the trends shaping and driving the global chronic kidney disease market.
- Quantify patient populations in the global chronic kidney disease market to improve product design, pricing, and launch plans.
About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff will help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.
Browse all Pharmaceuticals research reports at Fast Market Research
You may also be interested in these related reports:
- EpiCast Report: Chronic Myeloid Leukemia - Epidemiology Forecast to 2022
- EpiCast Report: Pediatric Respiratory Syncytial Virus Infection and Prophylactic Populations in the US - Epidemiology Forecast to 2022
- EpiCast Report: Chronic Heart Failure Epidemilogy Forecast to 2022
- EpiCast Report: Alzheimer's Disease - Epidemiology Forecast to 2022
- EpiCast Report: Crohn's Disease Epidemiology Forecast to 2022
- EpiCast Report: Meningococcal Disease - Epidemiology Forecast to 2022
- EpiCast Report: Systemic Lupus Erythematosus Epidemiology Forecast to 2022
- EpiCast Report: Atopic Dermatitis - Epidemiology Forecast to 2022
- EpiCast Report: Idiopathic Pulmonary Fibrosis - Epidemiology Forecast to 2022
- EpiCast Report: Asthma - Epidemiology Forecast to 2022